Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
GlobeAlert Desk · curated from South China Morning Post · East Asia
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- Second jury cant agree on underworld murder chargeAttacks & Assaults · Japan · 3h ago
- Black clover season 2 episode 7 recap ending explained who killed megicula and what happened to gajaAttacks & Assaults · Japan · 8h ago
- Mother of japanese abducted by n. korea urges resolution 49 years onKidnappings · North Korea · 19h ago